PharmGKB Summary: Very Important Pharmacogene Information for Angiotensin-converting Enzyme

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2009 Nov 10

PMID 19898265

Citations 7

Authors

Caroline F Thorn

Teri E Klein

Russ B Altman

Affiliations

Soon will be listed here.

Citing Articles

Exploring potential drug targets for SLE through Mendelian randomization and network pharmacology.

Xu Y, Wang Z, Jia T, Liang S PLoS One. 2025; 20(1):e0316481.

PMID: 39823480 PMC: 11741580. DOI: 10.1371/journal.pone.0316481.

Pharmacogenomic and Statistical Analysis.

Bai H, Zhang X, Bush W Methods Mol Biol. 2023; 2629:305-330.

PMID: 36929083 DOI: 10.1007/978-1-0716-2986-4_14.

Pharmacogenomics and Pharmacogenetics: In Silico Prediction of Drug Effects in Treatments for Novel Coronavirus SARS-CoV2 Disease.

Cafiero C, Re A, Micera A, Palmirotta R, Monaco D, Romano F Pharmgenomics Pers Med. 2020; 13:463-484.

PMID: 33116761 PMC: 7568633. DOI: 10.2147/PGPM.S270069.

Analysis of population-specific pharmacogenomic variants using next-generation sequencing data.

Ahn E, Park T Sci Rep. 2017; 7(1):8416.

PMID: 28871186 PMC: 5583360. DOI: 10.1038/s41598-017-08468-y.

Pharmacogenomics of breast cancer therapy: an update.

Westbrook K, Stearns V Pharmacol Ther. 2013; 139(1):1-11.

PMID: 23500718 PMC: 3660522. DOI: 10.1016/j.pharmthera.2013.03.001.

References

Bosse Y, Vohl M, Dumont M, Brochu M, Bergeron J, Despres J . Influence of the angiotensin-converting enzyme gene insertion/deletion polymorphism on lipoprotein/lipid response to gemfibrozil. Clin Genet. 2002; 62(1):45-52. DOI: 10.1034/j.1399-0004.2002.620106.x. View

Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F . An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990; 86(4):1343-6. PMC: 296868. DOI: 10.1172/JCI114844. View

Danser A, Koning M, Admiraal P, Sassen L, Derkx F, Verdouw P . Production of angiotensins I and II at tissue sites in intact pigs. Am J Physiol. 1992; 263(2 Pt 2):H429-37. DOI: 10.1152/ajpheart.1992.263.2.H429. View

Bray P, Cannon C, Goldschmidt-Clermont P, Moye L, Pfeffer M, Sacks F . The platelet Pl(A2) and angiotensin-converting enzyme (ACE) D allele polymorphisms and the risk of recurrent events after acute myocardial infarction. Am J Cardiol. 2001; 88(4):347-52. DOI: 10.1016/s0002-9149(01)01677-0. View

Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H . The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci. 2005; 21(3):733-40. DOI: 10.1111/j.1460-9568.2005.03912.x. View

Miners J, Baig S, Palmer J, Palmer L, Kehoe P, Love S . Abeta-degrading enzymes in Alzheimer's disease. Brain Pathol. 2008; 18(2):240-52. PMC: 8095507. DOI: 10.1111/j.1750-3639.2008.00132.x. View

Arnett D, Davis B, Ford C, Boerwinkle E, Leiendecker-Foster C, Miller M . Pharmacogenetic association of the angiotensin-converting enzyme insertion/deletion polymorphism on blood pressure and cardiovascular risk in relation to antihypertensive treatment: the Genetics of Hypertension-Associated Treatment (GenHAT) study. Circulation. 2005; 111(25):3374-83. DOI: 10.1161/CIRCULATIONAHA.104.504639. View

Zee R, Rao V, Paster R, Sweet C, Lindpaintner K . Three candidate genes and angiotensin-converting enzyme inhibitor-related cough: a pharmacogenetic analysis. Hypertension. 1998; 31(4):925-8. DOI: 10.1161/01.hyp.31.4.925. View

Geel P, Pinto Y, Zwinderman A, Henning R, van Boven A, Jukema J . Increased risk for ischaemic events is related to combined RAS polymorphism. Heart. 2001; 85(4):458-62. PMC: 1729671. DOI: 10.1136/heart.85.4.458. View

10.

Lennestal R, Olausson P, Kallen B . Maternal use of antihypertensive drugs in early pregnancy and delivery outcome, notably the presence of congenital heart defects in the infants. Eur J Clin Pharmacol. 2009; 65(6):615-25. DOI: 10.1007/s00228-009-0620-0. View

11.

Johnson J, Zineh I, Puckett B, McGorray S, Yarandi H, Pauly D . Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003; 74(1):44-52. DOI: 10.1016/S0009-9236(03)00068-7. View

12.

Johnson A, Gong Y, Wang D, Langaee T, Shin J, Cooper-DeHoff R . Promoter polymorphisms in ACE (angiotensin I-converting enzyme) associated with clinical outcomes in hypertension. Clin Pharmacol Ther. 2008; 85(1):36-44. PMC: 2709290. DOI: 10.1038/clpt.2008.194. View

13.

Yu Y, Niu T, Venners S, Zhang Y, Chen C, Huang A . Associations of baseline blood pressure levels and efficacy of Benazepril treatment with interaction of alpha-adducin and ACE gene polymorphisms in hypertensives. Clin Exp Hypertens. 2005; 27(1):83-94. DOI: 10.1081/ceh-200044273. View

14.

Rosskopf D, Michel M . Pharmacogenomics of G protein-coupled receptor ligands in cardiovascular medicine. Pharmacol Rev. 2008; 60(4):513-35. DOI: 10.1124/pr.108.000612. View

15.

Marian A, Safavi F, Ferlic L, Dunn J, Gotto A, Ballantyne C . Interactions between angiotensin-I converting enzyme insertion/deletion polymorphism and response of plasma lipids and coronary atherosclerosis to treatment with fluvastatin: the lipoprotein and coronary atherosclerosis study. J Am Coll Cardiol. 2000; 35(1):89-95. DOI: 10.1016/s0735-1097(99)00535-5. View

16.

Harrap S, Tzourio C, Cambien F, Poirier O, Raoux S, Chalmers J . The ACE gene I/D polymorphism is not associated with the blood pressure and cardiovascular benefits of ACE inhibition. Hypertension. 2003; 42(3):297-303. DOI: 10.1161/01.HYP.0000088322.85804.96. View

17.

Boubred F, Vendemmia M, Garcia-Meric P, Buffat C, Millet V, Simeoni U . Effects of maternally administered drugs on the fetal and neonatal kidney. Drug Saf. 2006; 29(5):397-419. DOI: 10.2165/00002018-200629050-00004. View

18.

Kohno M, Yokokawa K, Minami M, Kano H, Yasunari K, Hanehira T . Association between angiotensin-converting enzyme gene polymorphisms and regression of left ventricular hypertrophy in patients treated with angiotensin-converting enzyme inhibitors. Am J Med. 1999; 106(5):544-9. DOI: 10.1016/s0002-9343(99)00067-4. View

19.

Dudley C, Keavney B, Casadei B, Conway J, Bird R, Ratcliffe P . Prediction of patient responses to antihypertensive drugs using genetic polymorphisms: investigation of renin-angiotensin system genes. J Hypertens. 1996; 14(2):259-62. DOI: 10.1097/00004872-199602000-00016. View

20.

Kitsios G, Zintzaras E . ACE (I/D) polymorphism and response to treatment in coronary artery disease: a comprehensive database and meta-analysis involving study quality evaluation. BMC Med Genet. 2009; 10:50. PMC: 2700093. DOI: 10.1186/1471-2350-10-50. View